Floatz logo

Epsametostat

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Haihe Biopharma Co., Ltd.Small moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

127 Active assets in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Adriamycin
BeBetter Med Inc
Phase 4BBB
Prednisone
Tarapeutics Science Inc.
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB
(+)-Vincristine
BeBetter Med Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Epsametostat is also rated in:

follicular lymphomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
epithelioid sarcomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
cancerActive
CC
Indicative · Phase 1/2
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →